New York 18 April 2019:
The Report “Hemophilia
A Treatment Market
[By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs
(Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By
Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy)
and By Regions]: Market Estimate & Forecast, 2016 - 2022” The global hemophilia a treatment
market size to reach $8 billion by 2026 as per a new study released by Polaris
Market Research.
Request for sample of
this research report @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-sample
Hemophilia A patients have begun to
shift from short acting to EHL factors and from on demand therapies to
prophylactics. The increasing prevalent population of Hemophilia A and the rise
in demand of the prophylactics treatments in developed markets will have a
great impact on this market.
According to the US Centers for
Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male
births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the
United States is estimated to be about 20,000 individuals. Approximately 75% of
people with hemophilia around the world still receive inadequate treatment or
have no access to treatment.
As of January 2018, there are over
450 reported Clinical Trials for Hemophilia A with 50+ trials currently
actively ongoing. Out of all the trials, 120+ studies are funded by the
pharmaceutical companies alone. The major players with drugs in Phase III are
Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La
Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd,
Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.
Polaris Market Research expects
that with the expected launch of the promising treatments, the market is
expected to expand in Hemophilia A segment. The United States dominates the
Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis
segments are predicted to be the fastest growing segment whereas the on-demand
therapy segment is expected to contribute close to ~50% to the market during
the forecast period. With the increase in the R&D investments and rising
drug innovations in this field, the market is expected to significantly expand
in the next five years.
Browse summary of
this report with TOC @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market
RNA based therapeutics and curative
gene therapies are rapidly progressing through clinical development and are
seen as an attractive segment of this market.
Polaris Market Research has
provided the forecasts of the Global Hemophilia A Market from 2016-2022. The
major segments which has been investigated in the global market from 2016-2022
are:
·
Market
Analysis by Hemophilia A treatment
·
Market
Analysis by Treatments/Marketed Drugs
·
Market
Analysis by G7 countries
The
Marketed Therapies undertaken in forecast from 2016-2022 are:
·
Afstyla
Sales Forecast-2016-2022
·
Eloctate
Sales Forecast-2016-2022
·
Hemlibra
Sales Forecast-2016-2022
·
Kogenate
FS Sales Forecast-2016-2022
·
Kovaltry
Sales Forecast-2016-2022
·
Nuwiq
Sales Forecast-2016-2022
·
Obizur
Sales Forecast-2016-2022
The
Major Indications in Hemophilia A Therapy area:
·
Prophylaxis-Market
Forecast 2016-2022
·
On-demand
therapy-Market Forecast 2016-2022
·
Inhibitor
therapy- Market Forecast 2016-2022
Inquire before-buying
@ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/inquire-before-buying
The
Market Forecast of Hemophilia A Treatment by G7 Countries (2016-2022)
·
United
States- Market Forecast (2016-2022)
·
Germany-
Market Forecast (2016-2022)
·
France-Market
Forecast (2016-2022)
·
Italy-
Market Forecast (2016-2022)
·
Spain-
Market Forecast (2016-2022)
·
United
Kingdom- Market Forecast (2016-2022)
·
Japan-
Market Forecast (2016-2022)
Leading
Companies investigated in the Report are
·
CSL
Behring
·
Shire
·
Bayer
·
Biogen
·
Genentech
·
Bioverativ
·
Alnylam
Pharmaceuticals
·
Sanofi
(Genzyme)
·
BioMarin
Pharmaceutical
·
Hoffmann-La
Roche
·
Sinocelltech
Ltd.
·
Jiangsu
Chia-tai Tianqing Pharmaceutical Co.,Ltd
·
Octapharma
·
LFB
USA, Inc.
·
Novo
Nordisk A/S
·
Pfizer
Check for discount @ https://www.polarismarketresearch.com/industry-analysis/hemophilia-a-treatment-market/request-for-discount-pricing
About
Polaris Market Research
Polaris Market Research is a global
market research and consulting company. The company specializes in providing
exceptional market intelligence and in-depth business research services for our
clientele spread across different enterprises. We at Polaris are obliged to
serve our diverse customer base present across the industries of healthcare,
technology, semi-conductors and chemicals among various other industries
present around the world. We strive to provide our customers with updated
information on innovative technologies, high growth markets, emerging business
environments and latest business-centric applications, thereby helping them
always to make informed decisions and leverage new opportunities. Adept with a
highly competent, experienced and extremely qualified team of experts
comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver
value-added business solutions to our customers.
Contact
us
Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
No comments:
Post a Comment